competent cell kit Search Results


pcr amplification  (tiangen biotech co)
99
tiangen biotech co pcr amplification
Pcr Amplification, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/pmc11137092-247-17-24?v=tiangen+biotech+co
Average 99 stars, based on 1 article reviews
pcr amplification - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
tiangen cat  (tiangen biotech co)
96
tiangen biotech co tiangen cat
Tiangen Cat, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/pm39858134-100-14-14?v=tiangen+biotech+co
Average 96 stars, based on 1 article reviews
tiangen cat - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
pgem t easy cloning vector  (tiangen biotech co)
96
tiangen biotech co pgem t easy cloning vector
Pgem T Easy Cloning Vector, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/pmc08712286-63-8-13?v=tiangen+biotech+co
Average 96 stars, based on 1 article reviews
pgem t easy cloning vector - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
recombinant dnmt protein  (BPS Bioscience)
94
BPS Bioscience recombinant dnmt protein
a FPCK-1-1 cells were treated with 100 nM DBIC, DBIC-neg1, or 126 μM NOC18 every 3 days for a month before transfer to 3D culture. Spheroidal aggregate formation of FPCK-1-1 (or FPCKpP1-4 control) cells was assessed 3 d after plating. Scale bar, 50 μm. The data represent one of four separate experiments. b DBIC inhibited NO-induced sphere formation assessed 7 days post plating. Values are mean ± s.e.m. ( n = 4; *** P < 0.001 by two-way ANOVA with Bonferroni’s post hoc test). Treatments: None (black); vehicle (blue); DBIC (purple); DBIC-neg1 (green); NO (white); NO + DBIC (red); NO + DBIC-neg1 (orange). Colors correspond to code in representative micrographs in ( a ). c DBIC inhibits inflammation-related carcinogenesis in vivo. DBIC, DBIC-neg1 (25 mg/kg/day), or 1400 W (6 mg/kg/day) administered by i.p. injection from pre-implantation day 2 through day 35 post cell implantation. Regressive QR-32 cells (1 × 10 5 ) were implanted into mice on day 0 in a subcutaneously pre-inserted foreign body (gelatin sponge, 10 × 5 × 3 mm). ** P < 0.01, *** P < 0.001 vs. vehicle by χ 2 -test. d Time course of DBIC concentration in plasma after single i.p. administration (25 mg/kg) measured by LC-MS/MS. Values are mean ± s.e.m. ( n = 3). e Concentration of DBIC i n tumor tissue after 25 d of daily administration. Samples were analyzed 1 h after the final dose. For box plots, center line represents median; box limits are 25th and 75th percentiles. Whiskers represent minimum-maximum values ( n = 10). f SNO-DNMT3B in tumor tissue. Values are mean ± s.e.m. ( n = 3; ** P < 0.01 by two-tailed Student’s t -test). g Relative ratio of SNO-DNMT3B in human and mouse tumors. Biotin-switch and immunoblot assays were quantified by densitometry to calculate relative ratio of SNO-DNMT3B to total DNMT3B. Values are mean ± s.e.m. ( n = 6–7; * P < 0.05, ** P < 0.01 vs Normal by o n e-way ANOVA with uncorrected Fisher’s LSD post hoc test). h Schematic of <t>SNO-DNMT</t> mechanism of action on expression of specific genes associated with neoplasia via decreased methylation <t>of</t> <t>CpG</t> sites. Source data are provided as a Source data file.
Recombinant Dnmt Protein, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/pmc09899281-303-0-23?v=BPS+Bioscience
Average 94 stars, based on 1 article reviews
recombinant dnmt protein - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
quick pcr cloning kit  (BPS Bioscience)
85
BPS Bioscience quick pcr cloning kit
a FPCK-1-1 cells were treated with 100 nM DBIC, DBIC-neg1, or 126 μM NOC18 every 3 days for a month before transfer to 3D culture. Spheroidal aggregate formation of FPCK-1-1 (or FPCKpP1-4 control) cells was assessed 3 d after plating. Scale bar, 50 μm. The data represent one of four separate experiments. b DBIC inhibited NO-induced sphere formation assessed 7 days post plating. Values are mean ± s.e.m. ( n = 4; *** P < 0.001 by two-way ANOVA with Bonferroni’s post hoc test). Treatments: None (black); vehicle (blue); DBIC (purple); DBIC-neg1 (green); NO (white); NO + DBIC (red); NO + DBIC-neg1 (orange). Colors correspond to code in representative micrographs in ( a ). c DBIC inhibits inflammation-related carcinogenesis in vivo. DBIC, DBIC-neg1 (25 mg/kg/day), or 1400 W (6 mg/kg/day) administered by i.p. injection from pre-implantation day 2 through day 35 post cell implantation. Regressive QR-32 cells (1 × 10 5 ) were implanted into mice on day 0 in a subcutaneously pre-inserted foreign body (gelatin sponge, 10 × 5 × 3 mm). ** P < 0.01, *** P < 0.001 vs. vehicle by χ 2 -test. d Time course of DBIC concentration in plasma after single i.p. administration (25 mg/kg) measured by LC-MS/MS. Values are mean ± s.e.m. ( n = 3). e Concentration of DBIC i n tumor tissue after 25 d of daily administration. Samples were analyzed 1 h after the final dose. For box plots, center line represents median; box limits are 25th and 75th percentiles. Whiskers represent minimum-maximum values ( n = 10). f SNO-DNMT3B in tumor tissue. Values are mean ± s.e.m. ( n = 3; ** P < 0.01 by two-tailed Student’s t -test). g Relative ratio of SNO-DNMT3B in human and mouse tumors. Biotin-switch and immunoblot assays were quantified by densitometry to calculate relative ratio of SNO-DNMT3B to total DNMT3B. Values are mean ± s.e.m. ( n = 6–7; * P < 0.05, ** P < 0.01 vs Normal by o n e-way ANOVA with uncorrected Fisher’s LSD post hoc test). h Schematic of <t>SNO-DNMT</t> mechanism of action on expression of specific genes associated with neoplasia via decreased methylation <t>of</t> <t>CpG</t> sites. Source data are provided as a Source data file.
Quick Pcr Cloning Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/10__1161_slash_circresaha__109__213363-260-18-22?v=BPS+Bioscience
Average 85 stars, based on 1 article reviews
quick pcr cloning kit - by Bioz Stars, 2026-07
85/100 stars
  Buy from Supplier
z-competent cell kit  (G Biosciences)
90
G Biosciences z-competent cell kit
a FPCK-1-1 cells were treated with 100 nM DBIC, DBIC-neg1, or 126 μM NOC18 every 3 days for a month before transfer to 3D culture. Spheroidal aggregate formation of FPCK-1-1 (or FPCKpP1-4 control) cells was assessed 3 d after plating. Scale bar, 50 μm. The data represent one of four separate experiments. b DBIC inhibited NO-induced sphere formation assessed 7 days post plating. Values are mean ± s.e.m. ( n = 4; *** P < 0.001 by two-way ANOVA with Bonferroni’s post hoc test). Treatments: None (black); vehicle (blue); DBIC (purple); DBIC-neg1 (green); NO (white); NO + DBIC (red); NO + DBIC-neg1 (orange). Colors correspond to code in representative micrographs in ( a ). c DBIC inhibits inflammation-related carcinogenesis in vivo. DBIC, DBIC-neg1 (25 mg/kg/day), or 1400 W (6 mg/kg/day) administered by i.p. injection from pre-implantation day 2 through day 35 post cell implantation. Regressive QR-32 cells (1 × 10 5 ) were implanted into mice on day 0 in a subcutaneously pre-inserted foreign body (gelatin sponge, 10 × 5 × 3 mm). ** P < 0.01, *** P < 0.001 vs. vehicle by χ 2 -test. d Time course of DBIC concentration in plasma after single i.p. administration (25 mg/kg) measured by LC-MS/MS. Values are mean ± s.e.m. ( n = 3). e Concentration of DBIC i n tumor tissue after 25 d of daily administration. Samples were analyzed 1 h after the final dose. For box plots, center line represents median; box limits are 25th and 75th percentiles. Whiskers represent minimum-maximum values ( n = 10). f SNO-DNMT3B in tumor tissue. Values are mean ± s.e.m. ( n = 3; ** P < 0.01 by two-tailed Student’s t -test). g Relative ratio of SNO-DNMT3B in human and mouse tumors. Biotin-switch and immunoblot assays were quantified by densitometry to calculate relative ratio of SNO-DNMT3B to total DNMT3B. Values are mean ± s.e.m. ( n = 6–7; * P < 0.05, ** P < 0.01 vs Normal by o n e-way ANOVA with uncorrected Fisher’s LSD post hoc test). h Schematic of <t>SNO-DNMT</t> mechanism of action on expression of specific genes associated with neoplasia via decreased methylation <t>of</t> <t>CpG</t> sites. Source data are provided as a Source data file.
Z Competent Cell Kit, supplied by G Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+cell+kit/pm37119806-55-9-12?v=G+Biosciences
Average 90 stars, based on 1 article reviews
z-competent cell kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


a FPCK-1-1 cells were treated with 100 nM DBIC, DBIC-neg1, or 126 μM NOC18 every 3 days for a month before transfer to 3D culture. Spheroidal aggregate formation of FPCK-1-1 (or FPCKpP1-4 control) cells was assessed 3 d after plating. Scale bar, 50 μm. The data represent one of four separate experiments. b DBIC inhibited NO-induced sphere formation assessed 7 days post plating. Values are mean ± s.e.m. ( n = 4; *** P < 0.001 by two-way ANOVA with Bonferroni’s post hoc test). Treatments: None (black); vehicle (blue); DBIC (purple); DBIC-neg1 (green); NO (white); NO + DBIC (red); NO + DBIC-neg1 (orange). Colors correspond to code in representative micrographs in ( a ). c DBIC inhibits inflammation-related carcinogenesis in vivo. DBIC, DBIC-neg1 (25 mg/kg/day), or 1400 W (6 mg/kg/day) administered by i.p. injection from pre-implantation day 2 through day 35 post cell implantation. Regressive QR-32 cells (1 × 10 5 ) were implanted into mice on day 0 in a subcutaneously pre-inserted foreign body (gelatin sponge, 10 × 5 × 3 mm). ** P < 0.01, *** P < 0.001 vs. vehicle by χ 2 -test. d Time course of DBIC concentration in plasma after single i.p. administration (25 mg/kg) measured by LC-MS/MS. Values are mean ± s.e.m. ( n = 3). e Concentration of DBIC i n tumor tissue after 25 d of daily administration. Samples were analyzed 1 h after the final dose. For box plots, center line represents median; box limits are 25th and 75th percentiles. Whiskers represent minimum-maximum values ( n = 10). f SNO-DNMT3B in tumor tissue. Values are mean ± s.e.m. ( n = 3; ** P < 0.01 by two-tailed Student’s t -test). g Relative ratio of SNO-DNMT3B in human and mouse tumors. Biotin-switch and immunoblot assays were quantified by densitometry to calculate relative ratio of SNO-DNMT3B to total DNMT3B. Values are mean ± s.e.m. ( n = 6–7; * P < 0.05, ** P < 0.01 vs Normal by o n e-way ANOVA with uncorrected Fisher’s LSD post hoc test). h Schematic of SNO-DNMT mechanism of action on expression of specific genes associated with neoplasia via decreased methylation of CpG sites. Source data are provided as a Source data file.

Journal: Nature Communications

Article Title: Pivotal role for S -nitrosylation of DNA methyltransferase 3B in epigenetic regulation of tumorigenesis

doi: 10.1038/s41467-023-36232-6

Figure Lengend Snippet: a FPCK-1-1 cells were treated with 100 nM DBIC, DBIC-neg1, or 126 μM NOC18 every 3 days for a month before transfer to 3D culture. Spheroidal aggregate formation of FPCK-1-1 (or FPCKpP1-4 control) cells was assessed 3 d after plating. Scale bar, 50 μm. The data represent one of four separate experiments. b DBIC inhibited NO-induced sphere formation assessed 7 days post plating. Values are mean ± s.e.m. ( n = 4; *** P < 0.001 by two-way ANOVA with Bonferroni’s post hoc test). Treatments: None (black); vehicle (blue); DBIC (purple); DBIC-neg1 (green); NO (white); NO + DBIC (red); NO + DBIC-neg1 (orange). Colors correspond to code in representative micrographs in ( a ). c DBIC inhibits inflammation-related carcinogenesis in vivo. DBIC, DBIC-neg1 (25 mg/kg/day), or 1400 W (6 mg/kg/day) administered by i.p. injection from pre-implantation day 2 through day 35 post cell implantation. Regressive QR-32 cells (1 × 10 5 ) were implanted into mice on day 0 in a subcutaneously pre-inserted foreign body (gelatin sponge, 10 × 5 × 3 mm). ** P < 0.01, *** P < 0.001 vs. vehicle by χ 2 -test. d Time course of DBIC concentration in plasma after single i.p. administration (25 mg/kg) measured by LC-MS/MS. Values are mean ± s.e.m. ( n = 3). e Concentration of DBIC i n tumor tissue after 25 d of daily administration. Samples were analyzed 1 h after the final dose. For box plots, center line represents median; box limits are 25th and 75th percentiles. Whiskers represent minimum-maximum values ( n = 10). f SNO-DNMT3B in tumor tissue. Values are mean ± s.e.m. ( n = 3; ** P < 0.01 by two-tailed Student’s t -test). g Relative ratio of SNO-DNMT3B in human and mouse tumors. Biotin-switch and immunoblot assays were quantified by densitometry to calculate relative ratio of SNO-DNMT3B to total DNMT3B. Values are mean ± s.e.m. ( n = 6–7; * P < 0.05, ** P < 0.01 vs Normal by o n e-way ANOVA with uncorrected Fisher’s LSD post hoc test). h Schematic of SNO-DNMT mechanism of action on expression of specific genes associated with neoplasia via decreased methylation of CpG sites. Source data are provided as a Source data file.

Article Snippet: Recombinant DNMT protein (200–400 ng) was used to assess DNA methyltransferase activity against CpG-rich DNA substrates with a DNMT Direct Activity Assay Kit (BPS Biosciences, catalog #52035).

Techniques: In Vivo, Injection, Concentration Assay, Liquid Chromatography with Mass Spectroscopy, Two Tailed Test, Western Blot, Expressing, Methylation